ADAP stock: buy or sell?

ADAP stock price: $4.52 0.67% At close on January 17th, 2020

Updated on:
January 17th, 2020

3

Adaptimmune Therapeutics ended today at $4.52 and grew a slightly fine 0.67%. Friday was the 5th green day in a row, soaring 232.85%. On Jan 15th ADAP skyrocketed an astounding 9.01%.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform.

Should I buy ADAP stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Adaptimmune stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Adaptimmune stock a buy?

Banks and financial institutions post stock ratings everyday. At Stocks2.com, we collected 2 ratings published for ADAP stock in the last 30 days.

Is ADAP a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-5-7Raymond Jamesn/aOutperform
2019-5-30Citigroupn/aBuy

ADAP stock analysis

Daily outlook

Adaptimmune Therapeutics shares grew 0.67% to $4.52 today.

Adaptimmune Therapeutics shares grew 0.67% to $4.52 today. Since price and SMA200d lines crossed up on Monday, ADAP climbed $3.19 (239.85%). Today, SMA50d and SMA100d crossed up triggering a rise of 0.67%.

ADAP stock chart (daily)

Weekly outlook

Adaptimmune shares broke up the SMA line of 200d, closing at $4.52. Late December 2019 ADAP plummed a frightening -15.00% in just one week.

Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $1.44 resistance. Since SMA10d and SMA20w crossed up this week, ADAP price climbed $3.19 per share (239.85%).

ADAP stock chart (weekly)

ADAP stock price history

ADAP stock went public on May 6th, 2015 with a price of $19.251. Since then, ADAP stock lost a -76.50%, with a yearly average of -19.10%.

1: Adjusted price after possible price splits or reverse-splits.

ADAP stock historical price chart

ADAP stock reached 52-week highs on Tuesday at $6.00, and all-time highs 2015-06-16 with a price of 21.57.

ADAP stock price target is $7.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 2 price forecasts for ADAP stock released in the last month:
ADAP stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-5-7Raymond JamesReiterates$16.00$6.00-62.5%
2019-5-30CitigroupReiteratesn/a$8.00-
(in average)$16.00$7.00-56.0%
The price prediction for Adaptimmune Therapeutics stock is $7.00, moving in a range between $8.00 and $6.00. In average, analysts' outlook on ADAP price target is negative, downgrading the target by a -56.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Adaptimmune presented its financial report, posting an exceptional growth for the Earnings per Share (EPS). Analyst expected $-0.29 per share, but Adaptimmune Therapeutics posted $-0.36.
ADAP earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.05n/a
2017-Q2-n/a-0.04n/a
2017-Q32017-11-02-0.23-0.01n/a
2017-Q42018-03-15-0.25-0.29n/a
2018-Q12018-05-09-0.24-0.24n/a
2018-Q22018-08-02-0.28-0.48n/a
2018-Q32018-11-06-0.030.05n/a
2018-Q42019-02-27-0.29-0.36n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Adaptimmune annual turnover skyrocketed an outstanding 57.28% to $59.51 million USD from $37.83 marked in 2017. When comparing 2018 vs 2017, similarly, profit margin (that is, the net income divided by revenues) boosted a 24.87% to -160.51%.

ADAP annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2014$825 M-$0.00 M0.0%-
2014$0.58 M-99.93%$-12.21 M-2100.9%0.00%
2015$9.87 M1,598.45%$-22.06 M-223.5%80.66%
2015$8.98 M-9.04%$-23.00 M-256.2%4.27%
2016$14 M58.12%$-71.58 M-504.1%211.21%
2017$38 M166.47%$-70.14 M-185.4%-2.01%
2018$60 M57.28%$-95.51 M-160.5%36.18%

Quarterly financial results

Adaptimmune posted $1.48 M in sales for 2018-Q4, a -96.37% less compared to previous quarter. Reported quarter earnings marked $-36.17 million with a profit margin of -2,445.77%. Profit margin collapsed a -2,458.62% compared to previous quarter when profit margin was 12.85%. When comparing revenues to same quarter last year, Adaptimmune Therapeutics sales marked a bloodcurdling drop down and plunged a -65.36%.
ADAP quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$3 M-$-21.99 M-763.5%-
2017-Q2$4 M23.61%$-20.44 M-574.2%-7.05%
2017-Q3$27 M663.62%$-0.88 M-3.2%-95.70%
2017-Q4$4 M-84.29%$-27.26 M-638.5%3,005.13%
2018-Q1$8 M91.94%$-21.08 M-257.2%-22.69%
2018-Q2$9 M10.27%$-43.85 M-485.1%108.01%
2018-Q3$41 M351.34%$5.24 M12.9%-111.96%
2018-Q4$1 M-96.37%$-36.17 M-2445.8%-790.06%

Adaptimmune ownership

When you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.

Adaptimmune Therapeutics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.24% of all shares.

In case of Adaptimmune Therapeutics stock, 71.92% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ADAP stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Adaptimmune:

ADAPENZQURESGMO
Market cap$475.4 M$129.4 M$2.9 B$1.0 B
Total shares105.2 M47.6 M43.6 M115.9 M
Float shares53.2 M35.1 M31.3 M115.8 M
  - Institutional holdings (%)71.9%69.5%88.3%72.2%
  - Insider holdings (%)0.2%7.7%8.1%0.5%
Shares in short selling0.0%0.0%0.0%0.0%

ADAP summary

Friday, January 17th, 2020
Open$4.51
Close$4.52
Day range$4.30 - $4.82
Previous close$4.49
Session gain0.67%
Average true range$0.70
50d mov avg$1.43
100d mov avg$1.39
200d mov avg$2.45
Daily pattern
Weekly pattern lb02c

Adaptimmune performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Adaptimmune Therapeutics against Enzo Biochem, uniQure and Sangamo Therapeutics in the following table:
Stock3m6m12m
ADAPAdaptimmune Thera...365.98%38.23%-7.00%
ENZEnzo Biochem-15.79%-25.68%-25.68%
QUREuniQure57.19%-6.69%115.34%
SGMOSangamo Therapeut...6.37%-23.71%-23.84%

Adaptimmune competitors

We chose a few stocks to conform a list of Adaptimmune competitors to check if you are interested in investing in ADAP: